Key Highlights

• nib reported full-year results for the year ended 30 June 2026 on 24 August 2026.

• Group underlying operating profit (UOP) rose 9.1% to $260.9 million, from $239.2 million in FY25, landing within the $257 million to $267 million guidance range.

• Commentary on the release attributes the fall to unusually encouraging FY25 Investment returns and a low FY25 tax rate, so the two measures point in different directions for reasons worth understanding.

• It covers about 1.95 million customers across the two countries.

What does nib holdings (ASX:NHF)' FY26 result say about a health insurer that is reshaping itself around its core business? It shows a company delivering higher underlying Earnings while selling its travel arm and leaning harder on cost control, even as the largest division, Australian residents health insurance, earned less than a year earlier.

nib reported full-year results for the year ended 30 June 2026 on 24 August 2026. Group underlying operating profit (UOP) rose 9.1% to $260.9 million, from $239.2 million in FY25, landing within the $257 million to $267 million guidance range. Net profit after tax fell 5.9% to $186.9 million. Commentary on the release attributes the fall to unusually encouraging FY25 investment returns and a low FY25 tax rate, so the two measures point in different directions for reasons worth understanding.

What nib does and where earnings come from

nib is one of Australia's largest private health insurers by customers, and also operates in New Zealand. It covers about 1.95 million customers across the two countries.

Earnings come from several businesses. The biggest is Australian residents health insurance, where members pay premiums and nib pays claims, with a net Margin target of 6% to 7%. Next is the International segment, which insures overseas students and workers in Australia. New Zealand, a small and until recently loss-making business, is the third. Health services, including care navigation, and nib Thrive, which manages plans for participants in the National Disability Insurance Scheme (NDIS), make up the rest. nib Travel, which includes World Nomads, is being sold.

The FY26 numbers in more detail

Total income was about $3.85 billion, up 6.2%, with insurance Revenue of $3.69 billion, up 6.5%. The Operating Expense ratio improved by 110 basis points to 16.6%, which management links to productivity and automation. Around 86% of Australian residents claims were processed through automation of the release.

The segment picture matters more than the headline. Australian residents UOP fell 9.6% to $187.9 million, even though the division recorded encouraging sales and policyholder growth of 1.9%. The company pointed to elevated risk equalisation Volatility and rebate effects. Its net margin of 6.2% stayed inside the target range.

Offsetting that, the adjacent businesses did more of the lifting. International UOP rose 15.1%. New Zealand produced UOP of $27.5 million, compared with a small loss in FY25, helped by pricing and claims management. Health services moved into modest profit. nib Thrive generated UOP of $16.3 million, slightly below $16.9 million a year earlier, during what the company called significant sector reform.

The nib Travel sale and Capital management

The most significant strategic step is the agreed sale of nib Travel. nib is selling World Nomads, and its Australian and New Zealand travel insurance businesses, to separate buyers. Completion is expected in the first half of FY27, and nib expects about $97 million in net cash. About $24 million of that funds a 5 cent special dividend, with the remainder available for capital management.

The final dividend was 21.0 cents per share, including that special component, with a Record Date of 4 September 2026 and payment on 7 October 2026. The company's results material shows 34.0 cents in total for FY26, including the special dividend. It also raised its target Payout Ratio to 65% to 75%.

Excluding nib Travel, FY26 UOP was $256.1 million, up 10.2%. That is the more relevant base for the new guidance.

Sector conditions and competitive position

Private Health Insurance in Australia is a mature, heavily regulated market. Premium increases need government approval, claims Inflation is persistent, and insurers compete for members through price, product design and service. nib competes with larger rivals as well as other mid-sized funds.

Risk equalisation is a particular feature. It is an industry-wide mechanism that shares the cost of older or sicker members across insurers, so a fund's results can move with outcomes it does not fully control. nib has explicitly made its FY27 guidance and gross margin target subject to risk equalisation outcomes.

nib's Diversification is its main point of difference from pure domestic insurers. International and New Zealand operations now contribute meaningfully, yet Australian residents still accounted for roughly seven tenths of Group UOP, based on the segment figures above. Whether that diversification offsets pressure in the core is the central question for the next result.

In the NDIS plan management market, the company expects mandatory compliance reforms, which take effect in October 2027, to favour scaled and compliant providers.

Outlook and guidance

For FY27, nib guided to Group UOP of $265 million to $285 million, excluding nib Travel and subject to risk equalisation. At the midpoint of $275 million, that sits above the $256.1 million FY26 base excluding nib Travel, but guidance is an expectation, not a result. The company also expects lower one-off costs, a further improvement in the operating expense ratio, an Australian residents net margin within 6% to 7%, and positive UOP growth in health and insurance services.

Key risks and what to watch

First, risk equalisation can swing earnings, and the company has said so directly. Second, regulatory decisions on premium rises and rebates affect margins in the core business. Third, claims costs in both hospital and extras cover can rise faster than premiums.

Fourth, the nib Travel sale has yet to complete, so its timing and final proceeds remain to be confirmed. Fifth, International earnings depend on migration and student visa settings, which governments can change. Sixth, the NDIS is undergoing reform, and Thrive's profit fell slightly in FY26.

Investment returns are another variable, as the FY26 gap between UOP growth and the net profit decline shows.

Upcoming points to monitor include completion of the travel sale, the capital management decision on the balance of proceeds, any trading commentary at the annual general meeting, and the half-year result for the six months to 31 December 2026, due in early 2027 on the usual timetable.